Recent news on Filgrastim

Roche launches Neulastim  -  May 9, 2007
Express Pharma,Filgrastim, a white blood cell stimulating product decreases the risk of infection and hospitalisation as a result of chemotherapy-induced neutropenia.

Dr Reddy's launches Rituxan biosimilar in India  -  May 3, 2007
LabTechnologist.com,Reddy's sells Grafeel (filgrastim), a treatment that boosts white blood-cell production. Filgrastim is marketed by biotech giant Amgen as Neupogen.

Pharma firms see gains in niche areas  -  May 13, 2007
Times of India,In February this year, Ranbaxy signed a development and marketing agreement with Zenotech Laboratories for its first biosimilar product, G-CSF (filgrastim).

Dr Reddy's launches half-price version of MabThera  -  May 3, 2007
Pharma Times (subscription),...the second product to be launched by its biologics division; the first was Grafeel, its version of Amgen's neutropenia treatment Neupogen (filgrastim).

Ranbaxy eyes niche products in US, Europe  -  Apr 29, 2007
Business Standard,The company is also set to introduce its first biosimilar product, G-CSF (filgrastim), acquired through a global development and marketing pact with

Neulastim to check infections among cancer patients  -  Apr 10, 2007
Zee News,Filgrastim, a white blood cell stimulating product, has been shown to decrease the risk of infection and hospitalization as a result of chemotherapy-induced

Bone marrow donation: What to expect when you donate  -  Apr 6, 2007
MayoClinic.comThe medication, filgrastim (Neupogen), is typically given as an injection once a day for four or five days before your bone marrow stem cell donation.

A big heart  -  Mar 28, 2007
Milan News-Leader,Brousseau will face five days of injections of a drug called Filgrastim, which moves stem cells from the bone marrow into the blood stream, where it can be

Amgen earnings on the rise as Aranesp sales still grow  -  Apr 24, 2007
Pharma Times (subscription),As for its other drugs, Neupogen (filgrastim) and Neulasta (pegfilgrastim), used to boost white blood cells in patients on chemotherapy, saw combined sales

Amgen's First Quarter 2007 Revenue Increased 15 Percent to $3.7 ...  -  Apr 24, 2007
PharmaLive.com (press release),Combined worldwide sales of Neulasta(R) (pegfilgrastim) and NEUPOGEN(R) (Filgrastim), increased 14 percent to $1018 million in the first quarter of 2007

Amgen's First Quarter 2007 Revenue Increased 15 Percent to $3.7 ...  -  Apr 23, 2007
Genetic Engineering News (press release),Combined worldwide sales of Neulasta(R) (pegfilgrastim) and NEUPOGEN(R) (Filgrastim), increased 14 percent to $1018 million in the first quarter of 2007

Billion dollar babies—biotech drugs as blockbusters  -  Apr 3, 2007
Nature.com (subscription),The FDA approved the first biotech blockbusters, Epogen and Neupogen (filgrastim, Amgen's recombinant granulocyte-colony stimulating factor prescribed for

Intense Chemotherapy Fails for Gastric Cancer  -  Apr 20, 2007
MedPage Today,...leucovorin (250 mg/m 2 ), epidoxoorubicin (35 mg/m 2 ), 5-fluorouracil (500 mg/m 2 ), and glutathione (1.5 g/m 2 ) with the support of filgrastim.

Woman leads bone marrow drive effort  -  Apr 13, 2007
The Hillsdale Daily News,The process begins with the donor receiving five daily injections of Filgrastim, a drug that helps increase the number of blood cells in a person’s body.

DGAP-News: STADA Group results 2006 confirm -2-  -  Mar 28, 2007
Frankfurter Allgemeine Zeitung,After the completion of pre-clinical studies for the second biosimilar project Filgrastim was delayed, the beginning of clinical studies, from today's view,

Plymouth State helps to save lives  -  Mar 29, 2007
PSU The Clock (subscription),PBSC involves receiving daily injections of filgrastim to stimulate blood stem cell growth, then the donor's blood is drawn, the blood stem cells are

Changes in US law a good thing for local pharma  -  25 Feb 2007
Daily News & Analysis,Zenotech has tied up with Ranbaxy to develop and market its first bio-similar product, G-CSF - filgrastim, for preventing infections in cancer treatment.

Zenotech scouts for overseas partners  -  Feb 14, 2007
Moneycontrol.com,Having clinched a deal with Ranbaxy earlier this month for its first biosimilar GCSF (filgrastim), the Hyderabad-based company is in discussion with MNCs to

Zenotech ties up with Ranbaxy for EU market  -  Feb 7, 2007
Moneycontrol.com,...on Wednesday announced an agreement with Ranbaxy Laboratories Ltd for the development and marketing of its first biosimilar product G-CSF (Filgrastim).

Ranbaxy forays into biosimilar products  -  Feb 7, 2007
Hindu,...agreement with biopharma firm Zenotech for its first biosimilar product G-CSF (filgrastim) used for treatment of chemotherapy-induced infections.

Ranbaxy forays biosimilars via Zenotech tie-up  -  Feb 7, 2007
Business Standard,...announced the signing of a global development & marketing agreement with Zenotech Laboratories for its first biosimilar product, G-CSF (filgrastim).

Zenotech pacts with Ranbaxy for its Biosimilars  -  Feb 7, 2007
Andhra Cafe,...the signing of a global clinical development & marketing agreement with Ranbaxy Laboratories Ltd for its first biosimilar product, G-CSF (filgrastim).

Ranbaxy inks pact with Zenotech for G-CSF product  -  Feb 6, 2007
Myiris.com,N,C,F)* has signed a global development and marketing agreement with Zenotech Laboratories for its first biosimilar product, G-CSF (filgrastim).

US law promises new biz avenue for India  -  Feb 18, 2007
Central Chronicle,Zenotech Laboratories to produce its first biosimilar, a Granulocyte-colony stimulating factor (G-CSF; filgrastim) for chronic renal failure.

Growth Factors May Increase Risk of AML and MDS in Post-menopausal ...  -  Feb 15, 2007
Cancer Consultants (press release),One group of patients also received growth factors Neupogen® (filgrastim) or Leukine® (sargramostim), and the other group did not receive growth factors.

Growth Factors May Increase Risk of Secondary AML and MDS in Post ...  -  Feb 9, 2007
Cancer Consultants (press release),...cancer who receive adjuvant chemotherapy with Neupogen® (filgrastim) or Leukine® (sargramostim) may have an increased risk of developing secondary acute

Indian firm, Ranbaxy, eyes up biosimilars  -  Feb 9, 2007
BiopharmaReporter.com,...a granulocyte-colony stimulating factor (G-CSF; filgrastim), leading the way for Indian generic chemical-based companies to enter the biologics arena.

Dose-Intensive Chemotherapy with Stem Cell and Neupogen® Support ...  -  Feb 5, 2007
Cancer Consultants (press release),...carboplatin, and etoposide) administered with autologous stem cell and Neupogen (filgrastim) support improves median survival compared to standard doses

Dose-intensive Chemotherapy Improves Survival for Patients with ...  -  Feb 2, 2007
Cancer Consultants (press release),To counter these potentially life-threatening side effects, agents such as Neulasta® (pegfilgrastim) or Neupogen® (filgrastim) are often used.

Aranesp Data Eclipse Amgen's Fourth-Quarter Revenue Growth  -  Jan 26, 2007
BioWorld Online,And combined worldwide sales of Amgen's neutropenia drugs, Neulasta (pegfilgrastim) and Neupogen (filgrastim) increased 10 percent to $1 billion for the

Sprycel® Superior to High-Dose Gleevec for Gleevec-Resistant CML  -  18 Jan 2007
Cancer Consultants (press release),Another study suggested that the main side effect of Sprycel was cytopenias that could be corrected by the administration of Neupogen® (filgrastim) or

Park School host bone marrow drive for minorities  -  Jan 12, 2007
Baltimore Times,The donor is given daily injections of the drug filgrastim for five days prior to the collection. When ready, the blood is removed through a sterile needle

Research and Markets: Gain an Insight into the Financial ...  -  Dec 20, 2006
PharmaLive.com (press release),Neulasta (pegfilgrastim) is a sustained-duration formulation of Neupogen (filgrastim) formed by the addition of polyethylene glycol to granulocyte colony

Research and Markets: Gain an Insight into the Financial ...  -  Dec 20, 2006
PharmaLive.com (press release),Neulasta (pegfilgrastim) is a sustained-duration formulation of Neupogen (filgrastim) formed by the addition of polyethylene glycol to granulocyte colony

Doxorubicin/Cyclophosphamide Followed by Paclitaxel Inferior to ...  -  Dec 18, 2006
DG NewsFilgrastim and epoetin alpha were administered concurrently with EC/T. CEF is used widely in Canada for women with high-risk operable breast cancer,

She opens her arms to a stranger  -  Dec 14, 2006
Orlando Sentinel,But more and more, doctors are able to bypass surgery and collect those cells from the bloodstream with the help of a drug called filgrastim,

GenSci Expects Topical Molgramostim Gel Approval in 2007  Nov 3, 2006
GenSci has been the top biopharmaceutical manufacturer for Jintropin TM somatropin (human growth hormone, hGH), Scimax TM filgrastim (human granulocyte colony ... -Business Wire (press release), Donating stem cells  Oct 28, 2006
...bin Muhamed. For four days before the day of harvest, Siti was injected with a growth factor drug called filgrastim. “This growth ... -Malaysia Star, Intensive Neoadjuvant Therapy Benefits ER Negative and/or HER-2 ...  Oct 31, 2006
...from Italy have reported that weekly Platinol® (cisplatin), Ellence® (epirubicin), Taxol® (paclitaxel) with Neupogen® (filgrastim) support improves the ... -Cancer Consultants (press release), Findings from Germany, Netherlands and the United States in cancer ...  Oct 19, 2006
According to a recently published study from Germany, "A single injection of pegfilgrastim has been shown to be equivalent to daily filgrastim in enhancing ... -Therapeutics Daily (subscription) (press release), Amgen's Third Quarter 2006 Adjusted Earnings Per Share, Excluding ...  Oct 23, 2006
Combined worldwide sales of Neulasta(R) (pegfilgrastim) and NEUPOGEN(R) (Filgrastim), increased 13 percent to $998 million in the third quarter of 2006 versus ... -Genetic Engineering News (press release), Taking on new challenges  24 Sep 2006
Grafeel (generic name: filgrastim), a human Granulocyte Colony Stimulating Factor (hG-CSF), is a recombinant protein indicated for chemotherapy-induced ... -Financial Express

Weekly paclitaxel-carboplatin-gemcitabine triplet is effective ...  Sep 21, 2006
...to determine the pathologic complete response rate of advanced ovarian cancer to weekly paclitaxel plus gemcitabine and carboplatin with filgrastim, and assess ... -Therapeutics Daily (subscription)

Zacks.com announces that Richard Rhodes highlights the following ...  Sep 12, 2006
They manufacture and market four human therapeutic products, EPOGEN(R) (Epoetin alfa), NEUPOGEN(R) (Filgrastim), INFERGEN(R) (Interferon alfacon-1) and STEMGEN ... -Business Wire

STADA reorganizes Biosimilar  -  Nov 20, 2006
Ad-Hoc-News (Pressemitteilung),...financial risks ? Focus on the Epo-zeta and Filgrastim biosimilar projects - no further development of Interferon-beta ? Epo-zeta ...

DGAP-News: STADA reorganizes Biosimilar projects - Epo-zeta ...  -  Nov 20, 2006
Financial.de,For the Filgrastim project, pre-clinical trials are currently underway; the start of the clinical trials is expected by the end of 2006/beginning of 2007. ...

Stada to abandon Interferon-beta project for multiple sclerosis  -  Nov 20, 2006
Forbes,The move is part of the company's reorganisation of its Biosimilar projects. Stada announced that it is now focusing on its Epo-zeta and Filgrastim projects. ...

For biotech firms, US Democrats offer hope  -  Nov 24, 2006
Daily News & Analysis,Insulin, interferon alpha, erythropoietin, human growth hormone and filgrastim have all been in the market since 1991 or earlier. ...

DGAP-News: STADA: Growth after nine months of 2006: Sales +18% ...  -  Nov 13, 2006
Financial.de,...appropriate. Since the second quarter of 2006, the pre-clinical trials have been ongoing for the Filgrastim biosimiliar project. ...

Biological Response Modifiers in Cancer  -  Nov 15, 2006
Medscape (subscription)...agents such as granulocyte macrophage colony-stimulating factor (GM-CSF; sargramostim) and granulocyte colony-stimulating factor (G-CSF; filgrastim) have been ...

STADA reorganizes Biosimilar project Epo-zeta distribution rights ...  -  Nov 21, 2006
PipelineReview.com (press release),Epo-zeta), which is currently in the EU approval process, is still possible in late 2007, pre-clinical studies are just now running for the filgrastim project. ...

Pharma firms eye global injectables pie  Aug 18, 2006
This includes Amgen's Neupogen (Filgrastim) with 2002 sales of $1.5 billion, and GSK's Zofran (Ondansetron) with annual sales of $1.3 billion in 2003. ... -Financial Express

DGAP-News: STADA: Strong growth continues in H1/2006 - sales +18% ...  Aug 9, 2006
In the context of the development of the biosimilar products Erythropoietin, Filgrastim and Interferon beta-1a which is being carried out by BIOCEUTICALS ... -Financial.de

Bone marrow donors urgently needed  Jul 29, 2006
Side effects can include headache, bone or muscle pain, nausea, insomnia and fatigue while receiving daily injections of Filgrastim, for five days prior to the ... -Bradenton Herald

Neupogen® Decreases Toxicities Associated with Taxotere® ...  Aug 3, 2006
Researcher affiliated with a multicenter trial in Spain, Germany and Poland have reported that Neupogen (filgrastim) or Granocyte® (lenograstim) reduces ... -Cancer Consultants

Pliva and Mayne Amend G-CSF Deal  Aug 1, 2006
Pliva said that G-CSF has achieved significant developmental progress and has continually met comparability milestones with Amgen's Neupogen (filgrastim) that ... -Therapeutics Daily (subscription)

DME: Lifecycle management for biologics  Aug 2, 2006
Genentech's Rituxan (rituximab), while Maxygen is targeting G-CSF, a treatment currently dominated by Amgen's Neupogen (filgrastim)/Neulasta (pegfilgrastim ... -PharmaLive.com

Croatia's Pliva, Australia's Mayne confirm cooperation over ...  Jul 27, 2006
G-CSF is a generic version of Amgen Inc's Neupogen (filgrastim) for the regulation of white blood cell production in the treatment of cancer patients with ... -Life Style Extra

Combination Chemotherapy Followed by Radiation Therapy With or ...  Jul 27, 2006
...receive fluorouracil IV over 15 minutes, epirubicin IV over 1 hour, and cyclophosphamide IV over 1-2 hours on day 1. Patients also receive filgrastim (G-CSF ... -Community Dispatch

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--July 20, 2006--  Jul 20, 2006
Combined worldwide sales of Neulasta(R) (pegfilgrastim) and NEUPOGEN(R) (Filgrastim), increased 12 percent to $1,005 million in the second quarter of 2006 ... -Business Wire

High-dose Dense Chemotherapy and Radiation Therapy for Women with ...  Jul 21, 2006
...related news). Dose-dense regimens are usually supported by Neupogen® (filgrastim) or Neulasta® (pegfilgrastim). However, one ... -Cancer Consultants

ASCO Guidelines for Use of White Blood Cell Growth Factors ...  Jul 19, 2006
Oncology (ASCO) has published the 2006 update of recommendations for the use of white blood cell growth factors such as Neupogen® (filgrastim) or Neulasta ... -Cancer Consultants

Saved by a stranger - Jonathan Souweine meets the West Coast man ...  Jul 8, 2006
Shanks learned that he would be given five injections, over the course of five days, of a drug called filgrastim that increases the number of blood-forming ... -Daily Hampshire Gazette (subscription)

Barr Announces Offer of $2.2 Billion for PLIVA DD  Jun 27, 2006
...are seeking to develop and seek approval to market the product in the United States and Canada as a generic version of Amgen's NEUPOGEN(R) (filgrastim) product ... -Black Enterprise

DGAP-News: STADA: Approval documents for Erythropoietin biosimilar ...  Jun 29, 2006
In addition to Erythropoietin-zeta, the company is also carrying out development on two biosimilars from Filgrastim and Interferon beta-1a. ... -Financial.de

æ?¥æº?：生命ç»?纬  Jun 25, 2006
2002. Amgen's Erythropoetin patents expired in 2004 and the GCSG patent branded Filgrastim is due for patent expiry this year. Many ... -BioX

Priest's adult stem cell donation saves life of Kentucky mother of ...  Jun 29, 2006
...a home-health nurse would come to the Washington Theological College residence where Father Riley lived and give him a daily injection of filgrastim, a drug ... -Catholic Online

Catholic Priest's Adult Stem Cell Donation Saves Kentucky Woman's ...  Jun 29, 2006
For a week he was given a daily injection of filgrastim, a drug to promote white blood cell growth and eventually underwent a seven hour procedure at ... -LifeNews.com

Barr Announces Offer of $2.2 Billion for PLIVA dd  Jun 26, 2006
...are seeking to develop and seek approval to market the product in the United States and Canada as a generic version of Amgen's NEUPOGEN® (filgrastim) product. ... -Yahoo! News

Addition of Thalomid® to Chemotherapy Improves Survival in Small ...  Jun 30, 2006
...four chemotherapy agents). Patients received prophylactic Neupogen® (filgrastim) with each course of chemotherapy. If patients ... -Cancer Consultants

Barr Pharmaceuticals makes 2.2 bln usd bid for Croatia's PLIVA dd ...  Jun 27, 2006
...companies seek to develop and seek approval to market the product in the United States and Canada as a generic version of Amgen's NEUPOGEN (filgrastim) product ... -Forbes



Research and Markets: Aranesp, Neulasta and Enbrel have all Shown ...  16 May 2006
Neulasta (pegfilgrastim) is a sustained-duration formulation of Neupogen (filgrastim) formed by the addition of polyethylene glycol to granulocyte colony ... - Genetic Engineering News

DGAP-News: STADA: Very successful Q1/2006 - profit +30% (adjusted ...  May 14, 2006
Within the framework of the development of the biosimilar products Erythropoietin, Filgrastim and Interferon beta-1a, which is being carried out by ... - Financial.de

Major News Will Be Released for the International Pharmaceutical ...  May 12, 2006
LONDON, May 12 /PRNewswire/ -- Therapeutic Proteins, Ltd. ("TPL") has developed generic versions of filgrastim, interferon and erythropoietin, drugs whose ... - PR Newswire

Notiziario a cura di  May 12, 2006
Therapeutic Proteins, Ltd. ("TPL") has developed generic versions of filgrastim, interferon and erythropoietin, drugs whose branded versions collectively ... - ITNews

Dose-Dense Adjuvant Chemotherapy for Node-Positive Breast Cancer ...  May 5, 2006
Researchers from Germany have reported that dose-dense adjuvant chemotherapy delivered at 14-day intervals with Neupogen® (filgrastim) support improves ... - Cancer Consultants

Amgen's First Quarter 2006 Adjusted Earnings per Share, Excluding ...  Apr 20, 2006
Combined worldwide sales of Neulasta(R) (pegfilgrastim) and NEUPOGEN(R) (Filgrastim), increased 13 percent to $896 million in the first quarter of 2006 versus ... - Webbolt Business News

Injectable Generic Drugs: Prospects and Opportunities to 2010  Apr 28, 2006
...companies are also beginning to take an interest in some of the older high value biopharmaceuticals, including erythropoietin, filgrastim, recombinant insulin ... - Genetic Engineering News

Suggestion of Better Survival with Dose-Dense Chemotherapy in ...  Apr 28, 2006
All patients who received the dose-dense regimen also received treatment with Neupogen® (filgrastim) to reduce the likelihood of neutropenia. ... - Cancer Consultants

Taxotere®, Platinol®, and Herceptin® for Locally Advanced HER2 ...  Apr 24, 2006
...breast cancer. Neoadjuvant therapy was given for 12 weeks with each course supported by Neupogen® (filgrastim). Neoadjuvant therapy ... - Cancer Consultants





Long-Term Study Shows Safety of Neupogen® in AML Treatment  Mar 17, 2006
According to a recent article published in the journal Leukemia, the growth factor Neupogen® (filgrastim) is safe and effective when used in the treatment ... - Cancer Consultants

Supergen Announces Results from Combination Study in Cll Published ...  Mar 14, 2006
3-week intervals. Filgrastim, sulfamethoxazole/ trimethoprim, and acyclovir were administered prophylactically. For CLL patients ... - PharmaLive.com

Long-Term Study Shows Safety of Neupogen® Support in AML ...  Mar 17, 2006
Researchers affiliated with The International Acute Myeloid Leukemia Study have reported that the use of Neupogen (filgrastim) to support intensive induction ... - Cancer Consultants

SuperGen Announces Results From Combination Study in CLL Published ...  Mar 14, 2006
3-week intervals. Filgrastim, sulfamethoxazole/ trimethoprim, and acyclovir were administered prophylactically. Results For CLL ... - PR Newswire

Health: More Asian Pacific Islanders Needed For Marrow Donations  Feb 15, 2006
To increase the number of blood-forming cells in the bloodstream, donors receive daily injections of a drug called Filgrastim for five days before the ... - New California Media,

Intensive Therapy May Benefit Women With Breast Cancer of a Poor ...  Feb 14, 2006
An aggressive approach to chemotherapy consisting of adjuvant dose-intensive epirubicin and cyclophosphamide administered with filgrastim and progenitor cell ... - Cancerpage.com,

Amgen Continues Manufacturing Expansion with Additional $1 Billion ...  Feb 2, 2006
In Puerto Rico Amgen expects to enlarge its NEUPOGEN(R) (Filgrastim) and Neulasta(R) (pegfilgrastim) bulk protein manufacturing facility, licensed in 2005, as ... - Genetic Engineering News,

This site is for informational purposes only--it does not offer medical advice or sell health products. If you need assistance, contact your physician or healthcare professional